Thus, it is necessary to identify potent pri-miR-7–1/HuR inhibitors that will elevate miR-7 levels and lead to downregulation of its targets, including α-Syn, which could provide alternative solutions to PD therapy. Here, ELAVL1 is linked to Parkinson disease.